Gan & Lee Pharmaceuticals. (SHA:603087)

SHA:603087 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,064	902.78	2,443	2,890	3,306	2,825
Short-Term Investments	-	-	-	201.36	276.44	945.34
Trading Asset Securities	1,102	1,500	2,410	1,636	1,624	787.05
Cash & Short-Term Investments	3,166	2,403	4,853	4,728	5,206	4,557
Cash Growth	-37.51%	-50.48%	2.66%	-9.20%	14.24%	161.44%
Accounts Receivable	529.63	213.71	383.74	189.57	934.66	827.35
Other Receivables	29.01	31.89	1.63	0.99	0.16	0.96
Receivables	558.64	245.6	385.37	190.55	934.82	828.3
Inventory	1,125	1,053	860.51	648.65	651.33	493.48
Other Current Assets	118.5	89.07	76.73	97.36	77.95	80.55
Total Current Assets	4,968	3,791	6,176	5,664	6,870	5,960
Property, Plant & Equipment	3,824	3,882	3,886	3,661	2,595	2,149
Long-Term Investments	508.15	497.03	304.66	30	201.36	466.05
Other Intangible Assets	263.73	273.06	278.08	293.48	295.99	238.92
Long-Term Deferred Tax Assets	228.78	206.94	168.95	138.25	30.8	14.93
Long-Term Deferred Charges	1,399	924.91	821.97	743.19	588.87	544.27
Other Long-Term Assets	951.05	2,468	79.99	76.51	270.33	134.67
Total Assets	12,143	12,043	11,715	10,607	10,853	9,507
Accounts Payable	126.49	115.61	94.82	36.52	26.15	14.79
Accrued Expenses	168.73	183.44	192.54	190	173.04	183.07
Current Portion of Leases	-	1.33	2.18	5.69	5.07	-
Current Income Taxes Payable	15.86	1.49	1.42	1.35	106.32	53.35
Current Unearned Revenue	49.11	63.25	52.99	68.13	36.56	68.44
Other Current Liabilities	330.27	436	429.49	511.36	138.39	90.19
Total Current Liabilities	690.46	801.13	773.45	813.04	485.53	409.85
Long-Term Leases	2.58	3.31	5.45	8.33	12.17	-
Long-Term Unearned Revenue	164.68	168.92	179.63	187.63	141.98	125.77
Long-Term Deferred Tax Liabilities	-	12.11	-	-	36.15	31.78
Other Long-Term Liabilities	2.65	2.97	14	12.27	10.2	1.69
Total Liabilities	860.37	988.45	972.52	1,021	686.02	569.09
Common Stock	597.3	601.07	594.16	565.65	561.54	561.54
Additional Paid-In Capital	3,522	3,591	3,351	2,563	2,476	2,474
Retained Earnings	7,280	7,059	6,865	6,525	7,133	5,905
Treasury Stock	-120.69	-200.85	-71.36	-71.36	-	-
Comprehensive Income & Other	3.63	4.04	3.82	3.44	-3.44	-1.55
Total Common Equity	11,282	11,054	10,743	9,586	10,167	8,939
Minority Interest	-	-	0	-0.16	-0.16	-0.16
Shareholders' Equity	11,282	11,054	10,743	9,586	10,167	8,938
Total Liabilities & Equity	12,143	12,043	11,715	10,607	10,853	9,507
Total Debt	2.58	4.64	7.62	14.01	17.24	-
Net Cash (Debt)	3,164	2,399	4,846	4,714	5,189	4,557
Net Cash Growth	-37.52%	-50.50%	2.80%	-9.16%	13.86%	161.44%
Net Cash Per Share	5.38	4.06	8.55	8.37	9.25	8.55
Filing Date Shares Outstanding	595.31	598.96	590.05	561.54	561.54	561.54
Total Common Shares Outstanding	595.31	598.96	590.05	561.54	561.54	561.54
Working Capital	4,278	2,990	5,402	4,851	6,385	5,550
Book Value Per Share	18.95	18.46	18.21	17.07	18.11	15.92
Tangible Book Value	11,019	10,781	10,464	9,292	9,871	8,700
Tangible Book Value Per Share	18.51	18.00	17.73	16.55	17.58	15.49
Buildings	-	2,137	1,344	1,165	1,046	1,013
Machinery	-	1,601	1,443	1,237	1,263	1,171
Construction In Progress	-	1,262	2,007	2,003	874.91	410.12

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.